西他滨联合顺铂和吉西他滨联合奈达铂治疗复发转移性乳腺癌的疗效对比(1)
【摘要】 目的：研究西他滨联合顺铂和吉西他滨联合奈达铂治疗复发转移性乳腺癌的临床疗效。方法：回顾性分析笔者所在医院2008年1月-2014年1月收治的70例复发转移性乳腺癌患者的病历资料，并根据患者的治疗方案情况将其随机分为试验组和对照组各35例。试验组采用西他滨联合顺铂进行治疗，对照组采用吉西他滨联合奈达铂进行治疗。观察比较4个疗程后两组患者的临床疗效及不良反应发生情况。结果：经4个疗程后，试验组的治疗总有效率为48.57%，对照组的治疗总有效率为45.71%，两组的治疗总有效率比较差异无统计学意义(P>0.05)。试验组发生Ⅲ级白细胞下降2例，Ⅲ级血小板减少1例，Ⅰ度肾损害1例，Ⅱ度肾损害6例，胃肠道反应19例；对照组发生Ⅲ级白细胞下降1例，Ⅰ度肾损害1例，Ⅱ度肾损害0例，胃肠道反应2例；试验组的Ⅱ度肾损害和胃肠道反应发生率均明显高于对照组，差异均有统计学意义(P<0.05)。结论：西他滨联合顺铂和吉西他滨联合奈达铂治疗复发转移性乳腺癌的临床疗效相当，值得在临床中广泛推广。
【关键词】 西他滨； 顺铂； 奈达铂； 复发转移性乳腺癌
, http://www.100md.com
中图分类号 R737.9 文献标识码 B 文章编号 1674-6805(2014)35-0015-02
【Abstract】 Objective：To study the clinical effects of Decitabine plus Cisplatin and Gemcitabine plus Nedaplatin in the treatment of recurrent metastatic breast cancer.Method：The clinical data of 70 patients with recurrent metastatic breast cancer admitted to our hospital from January 2008 to January 2014 were retrospectively analyzed.According to the different treatment of patients，they were randomly divided into the experimental group and the control group，35 cases in each group.The experimental group was treated with Decitabine plus Cisplatin，and the control group was treated with Gemcitabine plus Nedaplatin. The clinical effect and adverse reaction after four courses between the two groups were observed and compared.Result：After the four courses，the total effective rate of experimental group was 48.57%，and the total effective rate of control group was 45.71%，there was no statistically significant difference in total effective rate between the two groups(P>0.05).Two cases occurred decrease of white blood cells in Ⅲ degree，1 case occurred Ⅲ degree thrombocytopenia，1 case occurred Ⅰ degree renal injury，six cases occurred Ⅱ degree renal injury and nineteen cases occurred gastrointestinal tract reaction in the experimental group.In the control group，1 case occurred decrease of white blood cells in Ⅲ degree，two cases occurred Ⅰ degree renal injury，nobody occurred Ⅱ degree renal injury，and two cases occurred gastrointestinal tract reaction.The Ⅱ degree renal injury and gastrointestinal tract reaction of experimental group were significantly higher than those of the control group，the differences were statistically significant(P<0.05).Conclusion：The clinical effects of Decitabine plus Cisplatin and Gemcitabine plus Nedaplatin in the treatment of recurrent metastatic breast cancer are equivalent，is worth in clinical promotion.
【Key words】 Decitabine； Cisplatin； Nedaplatin； Recurrent metastatic breast cancer, 百拇医药(李微绽 曾伟华 曹小龙)
【关键词】 西他滨； 顺铂； 奈达铂； 复发转移性乳腺癌
, http://www.100md.com
中图分类号 R737.9 文献标识码 B 文章编号 1674-6805(2014)35-0015-02
【Abstract】 Objective：To study the clinical effects of Decitabine plus Cisplatin and Gemcitabine plus Nedaplatin in the treatment of recurrent metastatic breast cancer.Method：The clinical data of 70 patients with recurrent metastatic breast cancer admitted to our hospital from January 2008 to January 2014 were retrospectively analyzed.According to the different treatment of patients，they were randomly divided into the experimental group and the control group，35 cases in each group.The experimental group was treated with Decitabine plus Cisplatin，and the control group was treated with Gemcitabine plus Nedaplatin. The clinical effect and adverse reaction after four courses between the two groups were observed and compared.Result：After the four courses，the total effective rate of experimental group was 48.57%，and the total effective rate of control group was 45.71%，there was no statistically significant difference in total effective rate between the two groups(P>0.05).Two cases occurred decrease of white blood cells in Ⅲ degree，1 case occurred Ⅲ degree thrombocytopenia，1 case occurred Ⅰ degree renal injury，six cases occurred Ⅱ degree renal injury and nineteen cases occurred gastrointestinal tract reaction in the experimental group.In the control group，1 case occurred decrease of white blood cells in Ⅲ degree，two cases occurred Ⅰ degree renal injury，nobody occurred Ⅱ degree renal injury，and two cases occurred gastrointestinal tract reaction.The Ⅱ degree renal injury and gastrointestinal tract reaction of experimental group were significantly higher than those of the control group，the differences were statistically significant(P<0.05).Conclusion：The clinical effects of Decitabine plus Cisplatin and Gemcitabine plus Nedaplatin in the treatment of recurrent metastatic breast cancer are equivalent，is worth in clinical promotion.
【Key words】 Decitabine； Cisplatin； Nedaplatin； Recurrent metastatic breast cancer, 百拇医药(李微绽 曾伟华 曹小龙)